Real-World Safety of Intravitreal Complement Inhibitor Avacincaptad Pegol for Geographic Atrophy.

Overall, 845 eyes of 590 patients (mean age, 81.8 ± 7.6 years; 71.9% female) received 5608 avacincaptad pegol injections.

Conversion occurred in 21 of 590 at-risk eyes (3.6%; 4.3% annualized) after a median of 3 injections (interquartile range, 3-5; range, 1-22).

At baseline, nAMD was present in 25.1% of fellow eyes but accounted for 38.1% of conversions, reflecting a higher subgroup conversion rate of 5.4% (6.7% annualized).

Among 26 eyes with quiescent nAMD, reactivation occurred in 1 eye (3.8%) after a treatment-free interval of 7.5 years.